{
    "ticker": "AKRO",
    "name": "Akero Therapeutics, Inc.",
    "description": "Akero Therapeutics, Inc. is a biotechnology company focused on developing transformative therapies for metabolic diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Founded in 2017 and based in San Francisco, California, Akero is dedicated to addressing the unmet medical needs of patients suffering from these chronic conditions. The company\u2019s lead product candidate, Efruxifermin (also known as AKR-001), is an innovative, once-weekly subcutaneous injection designed to reduce liver fat and inflammation. Akero is committed to advancing its research and clinical trials to provide effective treatment options for patients with severe liver diseases. The company employs a patient-centric approach, prioritizing safety and efficacy in its drug development program. With a robust pipeline and strategic collaborations, Akero aims to revolutionize the treatment landscape for metabolic liver diseases. The company also engages in research partnerships to support its innovative drug development processes and enhance its therapeutic offerings. Akero Therapeutics is committed to scientific excellence and has built a team of experienced professionals dedicated to bringing new therapeutic solutions to market for the benefit of patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2017",
    "website": "https://www.akerotx.com",
    "ceo": "Andrew Cheng",
    "social_media": {
        "twitter": "https://twitter.com/AkeroTx",
        "linkedin": "https://www.linkedin.com/company/akerotherapeutics/"
    },
    "investor_relations": "https://investors.akerotx.com",
    "key_executives": [
        {
            "name": "Andrew Cheng",
            "position": "CEO"
        },
        {
            "name": "Lynn Seely",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Efruxifermin (AKR-001)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Akero Therapeutics, Inc. | Innovating Treatments for Metabolic Diseases",
        "meta_description": "Akero Therapeutics, Inc. focuses on developing therapies for metabolic diseases, including NAFLD and NASH, with its lead candidate Efruxifermin. Learn more about Akero's mission and innovations.",
        "keywords": [
            "Akero Therapeutics",
            "Efruxifermin",
            "NAFLD",
            "NASH",
            "Biotechnology",
            "Metabolic Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Akero Therapeutics known for?",
            "answer": "Akero Therapeutics is known for developing innovative therapies for metabolic diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)."
        },
        {
            "question": "Who is the CEO of Akero Therapeutics?",
            "answer": "Andrew Cheng is the CEO of Akero Therapeutics, Inc."
        },
        {
            "question": "Where is Akero Therapeutics headquartered?",
            "answer": "Akero Therapeutics is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What is Akero's main product?",
            "answer": "Akero's main product candidate is Efruxifermin (AKR-001), which is designed to treat liver diseases."
        },
        {
            "question": "When was Akero Therapeutics founded?",
            "answer": "Akero Therapeutics was founded in 2017."
        }
    ],
    "competitors": [
        "PFE",
        "GILD",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "BIIB",
        "REGN",
        "CELG"
    ]
}